Compendia for coverage of off-label uses of drugs and biologics in an anticancer chemotherapeutic regimen
The topic of this assessment is the evaluation of drug compendia for the purpose of informing the Centers for Medicare & Medicaid Services (CMS) on decisions about coverage of off-label uses of drugs and biologics in anticancer treatment. This coverage is dictated by Section 1861(t)(2)(B) of the...
| Main Author: | |
|---|---|
| Corporate Authors: | , , , |
| Format: | eBook |
| Language: | English |
| Published: |
Rockville, Maryland
Agency for Healthcare Research and Quality
2007, May 7, 2007
|
| Series: | Technology assessment report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The topic of this assessment is the evaluation of drug compendia for the purpose of informing the Centers for Medicare & Medicaid Services (CMS) on decisions about coverage of off-label uses of drugs and biologics in anticancer treatment. This coverage is dictated by Section 1861(t)(2)(B) of the Social Security Act, which describes the reliance upon recommendations in compendia, specifically the AMA Drug Evaluations (AMA-DE; no longer in existence), American Hospital Formulary Service Drug Information (AHFS-DI), and United States Pharmacopeia Drug Information (USP-DI) |
|---|---|
| Item Description: | Title from PDF title page. - "Final report"--Cover |
| Physical Description: | 1 PDF file (iii, 135 pages) |